Immunome Reveals Strong Preclinical Data Showing Potent Anti-Tumor Activity of IM-1021

Immunome, Inc., a biotechnology firm based in Bothell, WA, USA, has recently shared encouraging preclinical data for its novel therapeutic candidate IM-1021 and the associated proprietary ADC payload, HC74. These findings were presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics held in Barcelona on October 24, 2024. The presentation included a poster titled "Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload," which detailed the preclinical performance of IM-1021 in both liquid and solid tumors.

The poster highlighted the impressive absorption, distribution, metabolism, and excretion (ADME) properties of HC74. Immunome is planning to submit an Investigational New Drug (IND) application for the IM-1021 program to the U.S. Food and Drug Administration (FDA) in the first quarter of 2025.

Jack Higgins, Ph.D., Chief Scientific Officer of Immunome, expressed optimism about the potential of IM-1021. He emphasized the importance of aligning the right target with the appropriate combination of antibody, linker, and payload to create transformative antibody-drug conjugates (ADCs). Higgins noted that the robust preclinical data for IM-1021 suggests it is a promising candidate for further development. The unique characteristics of HC74, including its significant potency in chemo-resistant cell lines, present exciting possibilities for clinical advancement. The company anticipates initiating clinical trials after receiving IND clearance to validate these preclinical findings.

Immunome is a clinical-stage biotech company dedicated to developing breakthrough targeted therapies aimed at improving outcomes for cancer patients. The company is advancing an innovative portfolio of therapeutic candidates. Its leadership team has previously been instrumental in the design, development, and commercialization of pioneering targeted cancer treatments, including ADCs.

In addition to its discovery-stage ADC portfolio, Immunome's pipeline features several promising candidates. These include AL102, a gamma secretase inhibitor currently in a Phase 3 trial for treating desmoid tumors, and IM-3050, a FAP-targeted radioligand. The company plans to submit INDs for both IM-1021 and IM-3050 in early 2025.

Immunome continues its mission to develop first-in-class and best-in-class therapies that target specific cancer markers, aiming to significantly improve patient outcomes by leveraging its expertise in antibody-drug conjugate technology and other targeted oncology approaches.